Combining Immunotherapy for Colorectal Cancer
The FDA approved a combination of two immunotherapeutics for treating patients with colorectal cancer.
Progress Against Cancer
The FDA approved a combination of two immunotherapeutics for treating patients with colorectal cancer.
The FDA approved two molecularly targeted therapeutics for use in combination to treat patients with metastatic melanoma.
The FDA approved a new anticancer therapeutic for treating certain patients with neuroendocrine tumors.
Breast cancer is the most commonly diagnosed cancer in the United States. In 2018, 266,120 women and 2,550 men are expected to receive the news that they have the disease, according to National Cancer Institute data.
Following dietary recommendations may reduce the risk of several cancers, a study in the AACR journal Cancer Research reports. Learn more.
The FDA approved pembrolizumab for patients with recurrent or metastatic cervical cancer that tests positive for PD-L1 and that has progressed despite chemotherapy.
The FDA expanded the use of the immunotherapy pembrolizumab for certain patients with an aggressive type of non-Hodgkin lymphoma.
Study: Initial treatment with an immune checkpoint inhibitor was associated with longer survival of patients with melanoma that had spread to the brain.
A recent study found that less than 13 percent of baby boomers were screened for the virus despite the recent approval of several effective treatments. Almost half of liver cancer cases in the United...
A study found declines in lung cancer death rates among women in the United States have lagged in two geographic hot spots.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More